US Patent 10,154,990: Claims Scope, Coverage Boundaries, and US Landscape
What does US Patent 10,154,990 actually claim?
US Drug Patent 10,154,990 (claims provided) is directed to methods of treating systemic scleroderma using a single defined small-molecule structure:
Active ingredient (core compound):
3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone
and salts thereof.
Claim set (as provided)
Claim 1 (core method, any salt):
- A method for treating systemic scleroderma comprising administering to a patient a therapeutically effective amount of the core compound or a salt.
Claim 2 (specific salt form):
- The method of Claim 1 where the compound is the monoethanesulfonate salt.
Claim 3 (combination therapy):
- The method of Claim 1 further administering an additional pharmacologically active substance selected from:
- anticholinergic agents
- beta-2 mimetics
- steroids
- PDE-IV inhibitors
- p38 MAP kinase inhibitors
- NK1 antagonists
- LTD4 antagonists
- EGFR inhibitors
- endothelin-antagonists
in combination with the core compound (or salt).
Claim 4 (composition framing of the combination):
- The method of Claim 3 where the core compound and the additional substance together comprise a pharmaceutical composition with one or more pharmaceutically acceptable carriers/excipients.
Claim 5 (monoethanesulfonate, explicit):
- A method for treating systemic scleroderma by administering the core compound specifically in the monoethanesulfonate salt form.
Practical claim structure
Coverage is built in three concentric layers:
- Monotherapy method for systemic scleroderma (Claim 1).
- Salt-specific method (monoethanesulfonate) (Claims 2 and 5).
- Combination-treatment method including a broad functional list of drug classes (Claim 3) with a composition embodiment (Claim 4).
What is the scope of the active ingredient limitation?
The claims lock the method to administration of a single structurally defined molecule (the named indolinone derivative) and “salts thereof.”
What this means for design-around
- If an accused product uses a different chemical entity (even with similar pharmacology), it typically falls outside the literal scope because the claim is not generic to a class of compounds.
- If the accused product uses the same compound but with a different salt, Claim 1 still reaches “salts thereof,” so a simple salt swap does not avoid coverage.
Salt coverage boundaries
- Claim 1: reaches the compound and any salt.
- Claims 2/5: add explicit coverage for monoethanesulfonate.
So, in terms of patent risk:
- Monoethanesulfonate is doubly covered.
- Other salts can still be captured under Claim 1.
What is the scope of the disease limitation (systemic scleroderma)?
All five claims require the indication: systemic scleroderma. That is a meaningful constraint.
Indication-based exposure
- Literal infringement requires administering the claimed compound(s) in a way that is tied to treating systemic scleroderma.
- If a product is marketed and used for a different scleroderma subset (or a different autoimmune fibrotic disease), the literal disease limitation may not be met. The claim language provided does not extend beyond systemic scleroderma.
What is the scope of “method for treating” and “therapeutically effective amount”?
These are functional dosing limitations:
- “Therapeutically effective amount” is broad and typically does not require a specific dose range in the claim set provided.
- The claims appear to cover any administration protocol that is sufficient for therapeutic effect under systemic scleroderma.
No further limits are visible in the claim text you supplied (no frequency, route, duration, or patient biomarker criteria).
How broad is the combination claim (Claim 3)?
Claim 3 is the largest commercial coverage vector because it allows pairing the core compound with a wide list of pharmacologically active substances.
Claim 3 combination classes (exclusive “selected from” list)
The additional agent can be from this set:
- anticholinergic agents
- beta-2 mimetics
- steroids
- PDE-IV inhibitors
- p38 MAP kinase inhibitors
- NK1 antagonists
- LTD4 antagonists
- EGFR inhibitors
- endothelin-antagonists
Key scope implications
- The claim does not require any mechanistic relationship beyond being “in combination.”
- It does not require the additional substance to be limited to a particular route, dosing schedule, or specific molecule within each class (at least as far as the claim text provided).
- If an accused regimen includes the core compound with any of these class members, Claim 3 is a direct target.
What does Claim 4 add?
Claim 4 frames the combination as a pharmaceutical composition that includes:
- the core compound and the additional substance
- pharmaceutically acceptable carriers or excipients
In practical terms, Claim 4 aligns with product-formulation or kit/composition assertions:
- It can reach situations where the combination is formulated together (or where the claim is interpreted to cover a composite pharmaceutical composition with carriers).
Claim 4 does not remove the “systemic scleroderma” limitation from the underlying method logic because it depends on Claim 3.
Claim 1 vs Claim 5: what is duplicated and what is not?
- Claim 1 is broader on salts but generic on the salt form.
- Claim 5 is narrower on salt form (monoethanesulfonate) but still method-based for systemic scleroderma.
So Claim 5 does not replace Claim 1; it adds a second, explicit anchor for monoethanesulfonate products.
What does this mean for freedom-to-operate in the US?
Direct infringement pathways
A US product or regimen is at risk if it:
- administers the named core compound (or any salt) at a therapeutically effective amount, and
- is used to treat systemic scleroderma, and
- for combination regimens, uses any member of the listed classes alongside the core compound.
Product scenarios by risk
- Monotherapy using monoethanesulfonate: high risk (Claims 1 + 2 + 5).
- Monotherapy using another salt of the same compound: risk remains (Claim 1).
- Combo therapy with the same compound plus any listed class drug: high risk (Claim 3; plus formulation risk if packaged/composed as in Claim 4).
- Same class of disease but different drug entity: lower risk on literal claim language, assuming no equivalency doctrine issues (not addressed by your supplied text).
How might this interact with generic and follow-on development strategies?
If a generic seeks approval for systemic scleroderma with the same API
- The claims are method claims tied to the active compound itself, not a specific manufacturing process.
- This creates a structure where the main competitive design target is not just bioequivalence but also labeling/indication and regimen.
If a follow-on developer changes salt, prodrug, or formulation
- Because Claim 1 includes “salts thereof,” salt changes alone do not eliminate risk.
- Claim 4 targets composition embodiments if a combination is packaged or formulated with carriers/excipients.
If a follow-on developer avoids listed combination classes
- Claim 3 is enumerated; avoiding those classes could reduce direct combination exposure.
- However, the monotherapy method (Claim 1) still exists, so avoidance only addresses Claim 3/4, not the entire patent.
Patent landscape: what can be concluded from the information provided
Your input includes only the claims (not bibliographic data, prosecution history, priority, continuation relationships, maintenance status, assignee, or citation map). Under those constraints, the only defensible landscape statements are about claim-directed coverage and what adjacent types of IP would typically matter.
What the landscape likely looks like (bounded to claim scope)
- This patent is a US method-of-treatment asset anchored to a single defined molecule and a disease.
- The “most relevant neighboring risks” in typical US practice are:
- other US patents covering the same API (polymorphs, other salts, formulations, or dosing regimens)
- other method patents covering the same indication with variations in combination partners or dosing schedules
- any Orange Book-related regulatory exclusivity tied to the same compound (if applicable)
But you have not provided the underlying patent record (assignee, filing date, expiration, continuation family members, or related US patents), so no specific claims or dates can be reliably mapped.
Key actionable coverage map (from the claim text)
Coverage checklist
| Dimension |
What triggers coverage |
Claim(s) |
| Active ingredient |
Administration of the named core compound or salt |
1 |
| Specific salt |
Administration of monoethanesulfonate |
2, 5 |
| Indication |
Systemic scleroderma treatment |
1-5 |
| Combination |
Core compound + agent selected from the 9 listed classes |
3 |
| Composition packaging |
Combination supplied as a pharmaceutical composition with carriers/excipients |
4 |
Key Takeaways
- US 10,154,990 is a systemic scleroderma method-of-treatment patent anchored to a single, fully specified molecule plus “salts thereof.”
- Monoethanesulfonate is explicitly claimed (Claims 2 and 5), but Claim 1 also reaches other salts, so salt-switching is not a clean design-around.
- The highest-risk exposure is combination regimens because Claim 3 includes a broad enumerated list of drug classes (9 categories).
- If a competitor plans a systemic scleroderma regimen using the same API, the analysis must track both indication alignment and whether the regimen includes any anticholinergic, beta-2 mimetic, steroid, PDE-IV, p38 MAPK, NK1, LTD4, EGFR, or endothelin-antagonist class member.
FAQs
1. Is monoethanesulfonate the only covered salt?
No. Claim 1 covers the compound “or a salt thereof,” while Claims 2 and 5 specifically cover monoethanesulfonate.
2. Does the patent cover monotherapy only?
No. It covers monotherapy (Claim 1) and combination therapy with an additional agent from the enumerated class list (Claim 3), plus a composition embodiment (Claim 4).
3. Can a different API avoid infringement?
Based on literal claim language, yes in principle, because the claims require administration of the specifically named core compound (or salts). The disease limitation still applies to systemic scleroderma.
4. Do the claims specify a dose or route?
In the provided claim text, no dose range, route, or schedule is specified; “therapeutically effective amount” is the only dosing standard.
5. What is the key commercial risk area for combination therapy?
The enumerated classes in Claim 3. Using the core compound in systemic scleroderma with any listed class agent creates direct claim exposure.
References
[1] US Patent 10,154,990, claims as provided (Claim 1-5).
